Bortezomib-cyclophosphamide-dexamethasone (VCD) versus bortezomib-thalidomide-dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis - Leiba, M; Kedmi, M; Duek, A (Br J Haematol, 2014)
. doi:10.1111/bjh.12946